Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.

MLA

Hart, Steven N., et al. “Determining the Frequency of Pathogenic Germline Variants from Exome Sequencing in Patients with Castrate-Resistant Prostate Cancer.” BMJ Open, vol. 6, no. 4, Apr. 2016, p. e010332. EBSCOhost, https://doi.org/10.1136/bmjopen-2015-010332.

APA

Hart, S. N., Ellingson, M. S., Schahl, K., Vedell, P. T., Carlson, R. E., Sinnwell, J. P., Barman, P., Sicotte, H., Eckel-Passow, J. E., Wang, L., Kalari, K. R., Qin, R., Kruisselbrink, T. M., Jimenez, R. E., Bryce, A. H., Tan, W., Weinshilboum, R., Wang, L., & Kohli, M. (2016). Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open, 6(4), e010332. https://doi.org/10.1136/bmjopen-2015-010332

Chicago

Hart, Steven N, Marissa S Ellingson, Kim Schahl, Peter T Vedell, Rachel E Carlson, Jason P Sinnwell, Poulami Barman, et al. 2016. “Determining the Frequency of Pathogenic Germline Variants from Exome Sequencing in Patients with Castrate-Resistant Prostate Cancer.” BMJ Open 6 (4): e010332. doi:10.1136/bmjopen-2015-010332.